|Home | About | Journals | Submit | Contact Us | Français|
Germline stem cells that produce oocytes in vitro and fertilization-competent eggs in vivo have been identified in and isolated from adult mouse ovaries. Here we describe and validate a FACS-based protocol that can be used with adult mouse ovaries and human ovarian cortical tissue to purify rare mitotically-active cells that exhibit a gene expression profile consistent with primitive germ cells. Once established in vitro, these cells can be expanded for months and spontaneously generate 35–50 µm oocytes, as determined by morphology, gene expression and attainment of haploid (1n) status. Injection of the human germline cells, engineered to stably express GFP, into human ovarian cortical biopsies leads to formation of follicles containing GFP-positive oocytes 1–2 weeks after xenotransplantation into immunodeficient female mice. Thus, ovaries of reproductive-age women, like adult mice, possess rare mitotically-active germ cells that can be propagated in vitro as well as generate oocytes in vitro and in vivo.
Since the early 1950s, management of ovarian insufficiency and failure, including infertility due to aging or insults, was restricted by the belief that the oocyte-containing pool of follicles set forth at birth is not amenable to renewal1. In 2004, studies with mice challenged the idea of a fixed ovarian reserve being endowed during the perinatal period2. Based on results from several approaches, it was concluded that ovaries of adult mice possess rare female germline or oogonial stem cells (OSCs) that generate oocytes analogous to spermatogonial stem cell (SSC) support of sperm production in adult testes3. Although this study was criticized by many in the field4, OSCs were successfully isolated from neonatal and adult mouse ovaries several years later5,6. These cells stably proliferate in vitro for months5,6 and spontaneously generate what appear to be immature oocytes in culture6. Transplantation studies showed that GFP-expressing OSCs injected into ovaries of chemotherapy-conditioned adult mice differentiate into mature eggs that are ovulated, fertilize and produce viable offspring5. These findings, along with other studies of mice7–9, have opened the possibility of using OSCs as agents for transplantation and as targets for therapies designed to modulate ovarian function and fertility4,10. Additionally, identification of dormant OSCs in atrophic ovaries of aged mice, which resume in-vivo oogenesis when exposed to a young adult ovarian environment11, indicates that ovarian aging may be reversible10,12. However, any consideration of clinical utility of these cells requires firm evidence that comparable oocyte-producing cells exist in ovaries of reproductive-age women.
As a first step towards this goal, we assessed the protocol recently reported to obtain OSCs from adult mouse ovaries5. This approach relies on immunological detection of a putative cell-surface variant of DEAD box polypeptide 4 (Ddx4; also commonly referred to as mouse vasa homolog or Mvh), an evolutionarily conserved germ cell-specific RNA helicase13–15, coupled with cell sorting by use of magnetic beads. Two issues surfaced that we felt might preclude application of this protocol to isolate candidate OSCs from adult human ovaries. First, Ddx4 is widely considered to be a cytoplasmic protein, and thus its claimed detection on the outside of mouse OSCs is at odds with prior studies10,16. Second, even if a cell-surface variant of Ddx4 is expressed by mouse OSCs, immunomagnetic sorting is a relatively crude cell isolation approach that often results in enrichment of a desired cell type in fractions contaminated with non-targeted cells carried over during column washing and flushing steps. Magnetic bead sorting also does not distinguish between viable and damaged or dead cells, and does not allow simultaneous assessment of other cellular features such as yield, size or co-expression of additional markers. Our objectives were to initially test with mice whether or not OSCs possess an externally-exposed epitope of Ddx4, and if so to use this property for validation of a FACS-based protocol to purify viable OSCs from dispersed ovaries of adult mice. We then determined if this technology could also be used to purify an equivalent population of candidate OSCs from ovarian cortical tissue of healthy reproductive-age women.
The Ddx4 antibody used previously to isolate mouse OSCs by immunomagnetic sorting is a rabbit polyclonal against the COOH-terminus of the protein5. We obtained this antibody along with a goat polyclonal antibody against the NH2-terminus of Ddx4 for comparative studies. Immunofluorescence analysis of young adult (2-month-old) mouse ovaries using either antibody showed an identical pattern of Ddx4 expression that was restricted, as expected, to oocytes (Fig. 1a). We then used each antibody for immunomagnetic sorting of dispersed young adult mouse ovary tissue5. No cells were obtained in the bead fraction when the NH2 antibody was used; however, 5–8 µm cells bound to the magnetic beads were observed when the COOH antibody was used (Fig. 1b). Analysis of cells isolated with the COOH antibody revealed a germline gene expression pattern consistent with that reported for mouse OSCs isolated previously using immunomagnetic sorting5 (Supplementary Fig. S1). Although isolated oocytes assessed in parallel using the COOH antibody were always detected in the non-immunoreactive wash fraction (Fig. 1b), additional marker analysis of the Ddx4-positive viable cell fraction obtained by immunomagnetic sorting revealed several oocyte-specific mRNAs including newborn ovary homeobox (Nobox), zona pellucida glycoprotein 3 (Zp3) and growth differentiation factor 9 (Gdf9) (Supplementary Fig. S1). These findings indicate that while mouse oocytes do not show evidence of cell surface expression of Ddx4 when analyzed as individual entities (Fig. 1b), mouse oocytes are nonetheless a contaminating cell type following immunomagnetic sorting of OSCs from dispersed mouse ovary tissue. This outcome most likely reflects either a non-specific physical carry-over of small oocytes with OSCs during column washing and flushing or reactivity of cytoplasmic Ddx4 in plasma membrane-compromised (damaged) oocytes with the COOH antibody.
We therefore next tested reactivity of each antibody with dispersed mouse ovarian cells by FACS. In agreement with the magnetic bead sorting results, viable Ddx4-positive cells were obtained only when the COOH antibody was used (Fig. 1c). However, if the ovarian cells were fixed and permeabilized prior to FACS, Ddx4-positive cells were obtained using the NH2 antibody (Fig. 1c). Furthermore, if viable Ddx4-positive cells isolated by FACS using the COOH antibody were fixed, permeabilized and re-sorted, the same cell population was recognized by the NH2 antibody (Fig. 1d). As a final means to confirm validity of this OSC isolation method, fractions of cells at each step of the protocol were assessed by gene expression analysis using markers for germ cells [PR domain containing 1 with ZNF domain or Prdm1 (human gene ortholog, PRDM1; also commonly referred to as BLIMP1), developmental pluripotency-associated 3 or Dppa3 (human gene ortholog, DPPA3, also commonly referred to as STELLA), interferon induced transmembrane protein 3 or Ifitm3 (also commonly referred to as Fragilis; human gene ortholog, IFITM3), telomerase reverse transcriptase or Tert (human gene ortholog, TERT), Ddx4 (human gene ortholog, DDX4), and deleted in azoospermia-like or Dazl (human gene ortholog, DAZL)] and for oocytes (Nobox, Zp3, and Gdf9). Adult mouse ovarian tissue was minced and enzymatically digested, passed through a 70-µm filter to remove large tissue clumps, and then passed through a 35-µm filter to obtain the final fraction of cells for FACS. Every fraction of cells through each step of the protocol, with the exception of the Ddx4-positive viable cell fraction obtained by FACS, expressed all germline and oocyte markers (Fig. 1f). While FACS-sorted Ddx4-positive cells expressed all germline markers, no oocyte markers were detected (Fig. 1f). Thus, unlike the oocyte contamination observed when OSCs were isolated by immunomagnetic sorting using the Ddx4-COOH antibody (Supplementary Fig. S1), use of this antibody with FACS provides a superior strategy to obtain OSCs free of oocytes.
Using the COOH antibody with FACS, we consistently isolated viable DDX4-positive cells between 5–8 µm in diameter from human ovarian cortical tissue of all subjects analyzed, with a percent yield (1.7% ± 0.6% DDX4-positive versus total viable cells sorted; mean ± s.e.m., n = 6) that was comparable to the yield of OSCs from young adult mouse ovaries processed in parallel (1.5% ± 0.2% Ddx4-positive versus total viable cells sorted; mean ± s.e.m., n = 15). This percent yield is the incidence of these cells in the final pool of viable single cells sorted by FACS, which represents only a fraction of the total number of cells present in ovaries prior to processing. To estimate the incidence of OSCs per ovary, we used young adult mice to determine genomic DNA content per ovary (1,774.44 ± 426.15 µg; mean ± s.e.m., n = 10) and divided this value into genomic DNA content per fraction of viable cells sorted per ovary (16.41 ± 4.01 µg; mean ± s.e.m., n = 10). Assuming genomic DNA content per cell is equivalent, this allowed us to determine how much of the total ovarian cell pool was represented by the total viable sorted cell fraction obtained after processing. Using this correction factor, we estimated the incidence of OSCs per ovary to be 0.014% ± 0.002% [0.00926 × (1.5% ± 0.2%)]. With respect to OSC yield, this number varied across replicates but we consistently obtained between 250 to slightly over 1,000 viable Ddx4-positive cells from each young adult mouse ovary after FACS of dispersates initially prepared from a pool of 4 ovaries.
Analysis of freshly-isolated Ddx4/DDX4-positive cells from mouse and human ovaries (Fig. 2a,b) revealed a similar size and morphology (Fig. 2c,d) and a matched gene expression profile rich in markers for early germ cells17–19 (Prdm1/PRDM1, Dppa3/DPPA3, Ifitm3/IFITM3 and Tert/TERT; Fig. 2e). These findings agree with the morphology and gene expression profile of mouse OSCs reported earlier5,6. To further define characteristic features of Ddx4-positive cells obtained from adult ovaries using FACS, we first performed an in-vivo teratoma formation assay. We felt this was important since a recent study has reported the isolation of Oct3/4-positive stem cells from adult mouse ovaries that possess the teratoma-forming capacity of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs)20. As expected, 100% of NOD-SCID mice transplanted with 1 × 105 mouse ESCs used as a positive control (n = 3) developed teratomas within 3 weeks; however, no teratomas were observed in NOD-SCID mice transplanted in parallel with 1 × 105 Ddx4-positive cells freshly isolated from adult mouse ovaries (n = 3), even at 24 weeks post-transplant (Fig. 2f–h). Thus, while OSCs express numerous stem cell and primitive germ cell markers5,6 (see also Figs. 1f and and2e),2e), these cells are distinct from other types of pluripotent stem cells described to date.
We next assessed the ability FACS-purified mouse OSCs, engineered to express green fluorescent protein (GFP) through retroviral transduction after their establishment as actively-dividing germ cell-only cultures in vitro (see In-vitro characterization of candidate human OSCs below), to generate oocytes following transplantation into ovaries of adult female mice. To ensure the outcomes obtained were reflective of stable integration of the transplanted cells into the ovaries and also were not complicated by pre-transplantation induced damage to the gonads, we injected GFP-expressing mouse OSCs into ovaries of non-chemotherapy conditioned wild-type recipients at 2 months of age and animals were maintained for 5–6 months prior to analysis. Between 7–8 months of age, we induced the transplanted animals to ovulate with exogenous gonadotropins, after which their ovaries and any oocytes released into the oviducts were collected. Developing follicles containing GFP-positive oocytes were readily detected, along with host follicles containing GFP-negative oocytes, in ovaries of all females that received GFP-expressing mouse OSCs initially purified by FACS (Fig. 3a).
After oviductal flushing, complexes containing expanded cumulus cells surrounding centrally-located oocytes both lacking and expressing GFP were observed. Mixing of these complexes with sperm from wild-type males resulted in fertilization and development of preimplantation embryos, with those derived from fertilized GFP-positive eggs retaining GFP expression through the hatching blastocyst stage (Fig. 3b–d). From the five adult wild-type female mice transplanted with GFP-expressing OSCs 5–6 months earlier, a total of 31 cumulus-oocyte complexes were retrieved from the oviducts, 23 of which successfully fertilized to produce embryos. The presence of cumulus cells around each oocyte made it impossible for us to accurately determine the numbers of GFP-negative versus GFP-positive oocytes ovulated. However, evaluation of the 23 embryos produced following in-vitro fertilization (IVF) revealed that eight were GFP-positive, with all five mice tested releasing at least one egg at ovulation that fertilized to produce a GFP-positive embryo. These findings indicate that mouse OSCs purified by DDX4-COOH antibody-based FACS, like their previously reported counterparts isolated by immunomagnetic sorting5, generate functional oocytes in vivo. However, our data also show that chemotherapy conditioning prior to transplantation is not, as previously reported5, required for OSCs to engraft and generate functional oocytes in adult ovary tissue.
Using parameters described previously for in-vitro propagation of mouse OSCs5, adult mouse and human ovary-derived Ddx4/DDX4-positive cells were placed into defined cultures with mitotically-inactive mouse embryonic fibroblasts (MEFs) as feeders. Freshly-isolated OSCs could be established as clonal cell lines, and the colony formation efficiency for human OSCs not seeded onto MEFs ranged from 0.18% to 0.40%. Accurate assessment of colony formation efficiency could not be performed using MEFs as initial feeders, the latter of which greatly facilitates establishment of mouse and human OSCs in vitro. After 10–12 weeks (mouse) or 4–8 weeks (human) in culture, actively-dividing germ cell colonies became readily apparent (Supplementary Fig. S2). Once established and proliferating, the cells could be re-established as germ cell-only cultures in the absence of MEFs without loss of proliferative potential. Dual analysis of Ddx4/DDX4 expression and bromodeoxyuridine (BrdU) incorporation in MEF-free cultures revealed large numbers of double-positive cells (Fig. 4a–d), confirming that adult mouse and human ovary-derived OSCs were actively dividing. At this stage, mouse cells required passage at confluence every 4–5 d with cultures split 1:6–1:8 (estimated doubling time of 14 h; Fig. 4e). The rate of mouse OSC proliferation was approximately 2–3 fold higher than that of human OSCs maintained in parallel, the latter of which required passage at confluence every 7 d with cultures split 1:3–1:4.
Cell surface expression of Ddx4 remained detectable on the surface of more than 95% of the cells after months of propagation (Fig. 4f). The remaining cells not detected by FACS using the COOH antibody were large (35–50 µm in diameter) spherical cells spontaneously produced by mouse and human OSCs during culture, which exhibited cytoplasmic expression of Ddx4/DDX4 and will be described in detail in the next section. Gene expression analysis of the cultured cells confirmed maintenance of early germline markers (Fig. 4g). Several oocyte-specific markers were also detected in these cultures, and the significance of these data will be discussed in the following section. To extend the mRNA analyses of Prdm1/PRDM1, Dppa3/DPPA3 and Ifitm3/IFITM3, we performed immunofluorescence analysis of these three classic primitive germline markers17,18. All three proteins were easily and uniformly detected in mouse (Fig. 4h) and human (Fig. 4i) OSCs maintained in vitro. Notably, our detection of Ifitm3/IFITM3 in these cells agrees with a recent study reporting that this protein can also be used to isolate OSCs from mouse ovaries by immunomagnetic bead sorting21.
Consistent with results from others6, mouse OSCs cultured in vitro spontaneously generated large (35–50 µm in diameter) spherical cells that by morphology (Fig. 5a) and gene expression analysis (Fig. 5b,c) resembled oocytes. Peak levels of in-vitro oogenesis from mouse OSCs were observed within 24–48 h after each passage (Fig. 5d), followed by a progressive decline to nearly non-detectable levels each time the OSCs regained confluence. Parallel analysis of DDX4-positive cells isolated from adult human ovaries and maintained in vitro revealed that these cells, like mouse OSCs, also spontaneously generated oocytes as deduced from both morphological (Fig. 5f) and gene expression (Fig. 5c,g) analyses. The kinetics of in-vitro oogenesis from human OSCs differed slightly from mouse OSCs in that peak levels of oocyte formation were observed at 72 h after each passage (Fig. 5e). In addition to detection of many widely accepted oocyte markers [Ddx4/DDX4, Kit/KIT, Nobox/NOBOX, LIM homeobox protein 8 (Lhx8/LHX8), Gdf9/GDF9, and zona pellucida glycoproteins 1–3 (Zp1/ZP1, Zp2/ZP2 and Zp3/ZP3)]22–26, mouse and human OSC-derived oocytes also expressed the diplotene oocyte stage-specific marker, Y-box protein 2 (Ybx2/YBX2; also commonly referred to as Msy2/MSY2 in both species, as well as CONTRIN in humans) (Fig. 5c), which is essential for meiotic progression and gametogenesis in both sexes27,28. Through empirical testing of commercially-available antibodies using adult human ovarian cortical tissue as a positive control, we identified four such antibodies against oocyte markers that specifically reacted with immature oocytes present in adult human ovaries (DDX4, KIT, YBX2 and LHX8) (Supplementary Fig. S3); all four of these proteins were also detected in oocytes generated by human OSCs in vitro (Fig. 5g).
The presence of mRNA encoding the meiotic marker YBX2 in oocytes newly formed from human OSCs in vitro prompted us to next explore the prospects of meiotic entry in these cultures. Immunofluorescence analysis of human OSCs 72 h after passage identified cells with punctate nuclear localization of the meiosis-specific DNA recombinase, dosage suppressor of mck1 homolog (DMC1), and the meiotic recombination protein, synaptonemal complex protein 3 (SYCP3) (Fig. 5h). Both proteins are specific to germ cells and are necessary for meiotic recombination to proceed29–31. Furthermore, chromosomal DNA content analysis of human OSC cultures 72 h after passage revealed the presence of an expected diploid (2n) cell population; however, we also detected peaks corresponding to 4n and 1n cell populations, the latter being indicative of germ cells that had reached haploid status32 (Fig. 5i). In actively-dividing cultures of human fibroblasts analyzed as controls in parallel, we detected only 2n and 4n populations of cells (Supplementary Fig. S4a). Haploid (1n) cells were also detected in mouse OSC cultures observed following FACS-based chromosomal analysis (Supplementary Fig. S4b).
To confirm and extend the in-vitro observations of oogenesis from candidate human OSCs, in two final experiments DDX4-positive cells isolated from adult human ovaries were stably transduced with a GFP expression vector (GFP-hOSCs) to facilitate cell tracking. In the first experiment, approximately 1 × 105 GFP-hOSCs were re-aggregated with dispersed adult human ovarian cortical tissue. Numerous GFP-positive cells were observed, as expected, throughout the re-aggregated tissue (Fig. 6a). The aggregates were then placed in culture and assessed 24–72 h later by direct (live cell) GFP fluorescence. Within 24 h, several very large (≥ 50-µm) single cells had formed within the aggregates, many of which were enclosed by smaller GFP-negative cells in tightly compact structures resembling follicles; these structures remained detectable through 72 h (Fig. 6b,c). We interpreted these findings as evidence that GFP-expressing human OSCs spontaneously generated oocytes that became enclosed by somatic (pregranulosa/granulosa) cells present in the adult human ovarian dispersates.
To more clearly determine if this was the case, we next injected approximately 1.3 × 103 GFP-hOSCs into adult human ovarian cortical tissue biopsies (2 × 2 × 1 mm), which were then xenografted into NOD-SCID female mice (n = 40 grafts total). Grafts were collected 7 or 14 d later for assessment of GFP expression. All human ovary grafts contained easily discernible primordial and primary follicles with centrally-located GFP-negative oocytes. Inter-dispersed among and often adjacent to these follicles, which were presumably present in the tissue prior to GFP-hOSC injection, were other immature follicles containing GFP-positive oocytes (Fig. 6d,f). Serial section histomorphometric analysis of three randomly selected human ovarian tissue grafts injected with GFP-hOSCs revealed the presence of 15–21 GFP-positive oocytes per graft 7 d after transplanting into mice (Supplementary Fig. S5). As controls, GFP-positive oocytes were never detected in human ovarian cortical tissue prior to GFP-hOSC injection (Fig. 6e) or in xenografts that received mock injections (vehicle without GFP-hOSCs) prior to transplantation into NOD-SCID mice (Fig. 6g). Dual immunofluorescence-based detection of GFP along with either the diplotene stage oocyte-specific marker, YBX2, or the oocyte-specific transcription factor, LHX8, identified many dual-positive cells distributed throughout xenografts injected with GFP-hOSCs (Fig. 6h). As expected, no GFP-positive oocytes were detected in human ovarian tissue prior to GFP-hOSC injection or in xenografts that did not receive GFP-hOSC injections (not shown; see Fig. 6e,g); however, the GFP-negative oocytes present in the tissue were consistently positive for YBX2 and LHX8 (Fig. 6h and Supplementary Fig. S3).
In 2004, a major paradigm shift in reproductive biology was proposed from a study in mice challenging the longstanding belief that ovaries of female mammals lose the capacity for oocyte generation prior to birth2. Although this change in thinking was initially met with resistance from some members of the scientific community due to its sharp deviation from traditional beliefs in the field4, subsequent studies have since independently demonstrated that mouse OSCs can be isolated from adult ovaries for long-term propagation in vitro5,6 and for generation of fertilization-competent eggs in vivo following intraovarian transplantation in chemotherapy-conditioned recipient female mice5,21. In addition, other work has reported that de-novo oocyte formation in adult mouse ovaries can be stimulated by small molecule inhibitors of histone deacetylases as well as by an as-yet unidentified factor(s) in the peripheral circulation of male mice7–9. However, the potential clinical relevance of these findings with mice has remained unclear due to a lack of definitive evidence that ovaries of reproductive-age women contain a comparable population of oocyte-producing germline cells that match the characteristic features of mouse OSCs.
As a first step towards accomplishing this, herein we describe in detail the conceptual and technical validation of a straightforward and highly repeatable FACS-based approach for the purification of viable OSCs from adult ovary tissue. The utility of an antibody directed against the COOH-terminus of Ddx4/DDX4 to isolate OSCs apparently reflects a differentiation-dependent switch in localization of this protein in female germ cells from the cell-surface (OSCs) to the cytoplasm (oocytes), with the latter being in accordance with traditional beliefs that Ddx4/DDX4 is a cytoplasmic protein in germ cells. The physiological significance of this change in localization remains to be determined; however, computer-based mapping of the Ddx4/DDX4 transmembrane spanning domain predicts that insertion of the COOH terminus of the protein across the cell membrane could potentially interfere with the RNA helicase domain10,33. Although additional work will be needed to test this, movement of proteins into and out of various cellular compartments is a post-translational mechanism commonly used by cells to regulate the activity of such proteins. In any case, we have incorporated this feature of Ddx4/DDX4 into a FACS-based protocol to demonstrate that a rare population of mitotically-active germ cells with a gene expression profile and growth characteristics remarkably similar to mouse OSCs can be reliably isolated from ovaries of healthy young women and propagated long-term in vitro.
Our successful purification of what appears to be, by all criteria tested, the human equivalent of mouse OSCs was facilitated by two main factors: nearly three years of work in our lab to test and refine the Ddx4/DDX4 antibody-based protocol for isolation of OSCs using FACS rather than immunomagnetic sorting as reported initially5, and rare access to entire ovarian cortical tissue that had been vitrified and cryopreserved following removal of both ovaries from women in their twenties and early thirties (Supplementary Fig. S6a,b). Recent studies of mouse OSCs by others have demonstrated the ability of these cells to generate immature oocytes in vitro6 (see also Fig. 5a–c) as well as oocytes that mature into developmentally-competent eggs in vivo5 (see also Fig. 3). Regarding the latter, it is notable that prior studies of mammalian germline stem cell transplantation using SSCs or OSCs have been performed with chemotherapy-conditioned hosts as recipients5,21,34,35, presumably to open niches for effective donor cell engraftment. Our observations show that for OSCs, adult females do not require chemotherapy conditioning prior to transplantation for these cells to effectively engraft in the ovaries and function long-term (≥ 5 months), at least as measured by their ability to generate oocytes that mature in follicles which yield fertilization-competent eggs following ovulation. Unfortunately, for ethical and legal reasons, as well as technical feasibility limitations related to a current lack of validated protocols for efficiently maturing human primordial follicles to the antral stage in vitro for isolation of metaphase II oocytes, our current endpoint analysis of the human equivalent cells could not be as comprehensive. Nonetheless, we have established a consistent and close parallelism between human ovary-derived DDX4-positive cells and mouse OSCs in terms of strategy of purification, yield from adult ovary tissue, morphology, primitive germline gene expression profile, in-vitro growth properties, mitotic activity, meiotic activity, and the ability to form oocytes in defined cultures in vitro and in injected ovary tissue in vivo.
Therefore, based on the multiple experimental lines of evidence reported herein we feel it is reasonable to conclude that these rare cells with cell-surface expression of DDX4 present in ovaries of reproductive-age women represent adult human OSCs. In addition to opening a new research field in human reproductive biology that was inconceivable less than ten years ago, clear evidence for the existence of these cells in women may offer new opportunities to expand on and enhance current fertility preservation strategies. For example, with assisted reproductive technologies involving cryopreservation of ovarian cortical tissue already in development for female cancer patients36,37, isolation and expansion of OSCs from this tissue before or after cryopreservation might prove useful for new fertility applications. In fact, we have found that these cells can be consistently obtained from cryopreserved and thawed human ovarian tissue samples, and that the cells per se can be cryopreserved and thawed months later with minimal loss for successful establishment in vitro (Supplementary Fig. S6c). In addition, the availability of a detailed protocol for purification of these newly-discovered cells from human ovary tissue provides us and others with a much more physiologically relevant in-vitro model system to study human female germ cell development compared to ESC- or iPSC-derived germline cells currently used as models for human female gametogenesis38–42.
Wild-type C57BL/6 and NOD-SCID mice were from Charles River Laboratories and Jackson Laboratories, respectively. Transgenic mice with germline-specific GFP expression (TgOG2)43–45 were obtained, bred and genotyped as described7,46. All animal protocols were reviewed and approved by the institutional care and use committee of Massachusetts General Hospital.
With written informed consent, ovaries were surgically removed from six female subjects between 22–33 years of age with Gender Identity Disorder for sex reassignment at Saitama Medical Center. The outer cortical layer was carefully removed, vitrified and cryopreserved47. For experiments, cryopreserved tissue was thawed using the Cryotissue Thawing Kit (Kitazato Biopharma). All experiments with human tissue were conducted without subject identifiers under a protocol reviewed and approved by the institutional review board of Massachusetts General Hospital (protocol number 2008P001640).
Polyclonal antibodies against the COOH- (ab13840; Abcam) or NH2- (AF2030; R&D Systems) terminus of DDX4 were from Abcam or R&D Systems, respectively.
Dissociated ovarian cells or isolated oocytes were processed by immunomagnetic sorting using streptavidin-conjugated microbeads (Miltenyi) or secondary antibody-conjugated Dynabeads (Invitrogen), as described5.
Antibody-labeled ovarian cell suspensions were subjected to FACS using a BD Biosciences FACSAria II cytometer (Harvard Stem Cell Institute), gated against negative controls (unstained cells and cell fractions processed without primary antibody).
Mouse ESCs (mESC v6.5) or freshly-isolated mouse OSCs were injected subcutaneously near the rear haunch of NOD/SCID female mice, which were then monitored weekly for up to 6 months for tumor formation.
Mouse and human OSCs were established on mitotically-inactivated immortalized MEFs and propagated in vitro, essentially as described5. To assess proliferation, MEF-free OSC cultures were treated with 10 µM BrdU (Sigma-Aldrich) for 48 h for dual immunofluorescence-based detection of BrdU incorporation and Ddx4/DDX4 expression, essentially as described5.
Fixed ovarian tissues, OSCs or oocytes were assessed by standard immunohistochemical or immunocytochemical methods using antibodies that recognize Ddx4/DDX4 (COOH terminus: ab13840, Abcam; NH2 terminus: AF2030, R&D Systems), Kit/KIT (sc1494, Santa Cruz Biotechnology), Prdm1/PRDM1 (ab81961, Abcam), Dppa3/DPPA3 (ab19878; Abcam), Ifitm3/IFITM3 (mouse: ab15592, human: ab74699; Abcam), DMC1 (ab96613, Abcam), SYCP3 (ab85621, Abcam), YBX2 (ab33164, Abcam) or LHX8 (ab41519, Abcam).
Chromosomal analysis of mouse and human OSCs was performed using a BD Biosciences FACSAria II cytometer, essentially as described32. Human fetal kidney fibroblasts (KEK 293, Invitrogen) were used as control somatic cells.
One µg of pBabe-Gfp vector DNA (Addgene plasmid repository #10668) was transfected (Lipofectamine, Invitrogen) into the Platinum-A retroviral packaging cell line (Cell Biolabs). Transduction of OSCs was performed using fresh viral supernatant in the presence of polybrene (Sigma-Aldrich). Mouse and human OSCs with expression of GFP were purified by FACS following an initial one week of propagation, and then expanded for two additional weeks before a second round of FACS purification to obtain cells used for experiments.
GFP-expressing mouse OSCs (1 × 104) were injected directly into each ovary of wild-type mice at 2 months of age. Between 7–8 months of age, transplanted mice were subjected to an induced ovulation protocol. Cumulus-oocyte complexes were collected from the oviducts and assessed by direct fluorescence microscopy for GFP expression. For in-vitro fertilization (IVF), cumulus-oocyte complexes were mixed wild-type sperm for 4–5 h, washed and transferred to KSOM-AA medium (Irvine Scientific). Light and fluorescence microscopic examination was performed every 24 h for a total of 144 h to monitor embryo development48. Ovarian tissue harvested at the time of oocyte collection was processed for immunohistochemical detection of GFP, as detailed46.
Dissociated human ovarian cortex was incubated with 35 µg ml−1 phytohemaglutannin (PHA; Sigma) along with 1×105 GFP-expressing human OSCs for 10 min at 37 C. The cell mix was pelleted to create the tissue aggregate, which was placed onto a Millicell 0.4-µm culture plate insert (Millipore) in OSC culture medium. Aggregates were incubated at 37 C in 5% CO2-95% air, and live-cell GFP imaging was performed 24, 48 and 72 h later.
Human ovarian cortical tissue injected with approximately 1.3 × 103 GFP-expressing human OSCs were grafted into NOD-SCID female mice49,50. Xenografts were removed 7 or 14 d after transplantation and processed for immunohistochemical detection of GFP expression46. For dual marker analysis, we performed immunofluorescence-based detection of GFP and either YBX2 or LHX8 (see Immunoanalysis).
All experiments were independently replicated at least three times. Quantitative data (means ± s.e.m. of combined results) were analyzed by one-way analysis of variance using Prism software, whereas qualitative images presented are representative of outcomes obtained in replicate experiments.
The authors thank L. Prickett-Rice and K. Folz-Donahue of the Harvard Stem Cell Institute Flow Cytometry Core Facility, and J. Groeneweg, for expert technical assistance. We also thank J.R. Mann and K.J. MacLaughlin for provision of TgOG2 transgenic mice. This work was supported by a Method to Extend Research in Time (MERIT) Award from the US National Institute on Aging (NIH R37-AG012279), the Henry and Vivian Rosenberg Philanthropic Fund, the Sea Breeze Foundation, and Vincent Memorial Hospital Research Funds. This work was conducted while D.C.W. was supported in part by a Ruth L. Kirschstein National Research Service Award (NIH F32-AG034809).
Author contributions Y.A.R.W., D.C.W. and J.L.T. designed the experiments, analyzed the data, and wrote the manuscript; Y.A.R.W. and D.C.W. conducted the experiments; Y.T., O.I. and H.S. collected, cryopreserved, and provided human ovarian cortical tissue; J.L.T. directed the project; all authors reviewed and approved the final manuscript for submission.
Competing interests statement J.L.T. declares interest in intellectual property described in US Patent 7,955,846 and is a co-founder of OvaScience, Inc. (Boston, MA); Y.A.R.W. and D.C.W. are scientific consultants for OvaScience, Inc. (Boston, MA); the remaining authors declare they have no competing financial interests.